Rahaf Altahan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rahaf Altahan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Ali Peer Zada
Department of Medical Genetics and Molecular Pathology, Pathology and Clinical Laboratory Medicine Administration King Fahad Medical City Riyadh Saudi Arabia
2 shared publications Ahmad Al-Zghoul
Flow cytometry Lab, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
1 shared publication- Alex Bourguignon
Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario Canada
1 shared publication - Areej Al Mugairi
Hematopathology Division, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh 11426, Saudi Arabia
1 shared publication Areej AlMugairi
Division of Hematopathology, Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia
1 shared publicationAziza Alswayyed
Pathology and Clinical Laboratory Medicine Administration King Fahad Medical City Riyadh Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 11 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1638994
Acquired platelet disorders
Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most recognized causes in clinical practice. Nevertheless, increasing evidence points to inflammation, particularly the profound dysregulation seen in sepsis, as a major contributor to abnormal platelet behavior. Although sepsis-associated platelet defects are frequent in practice and correlate with organ injury and adverse outcomes, they are rarely acknowledged in traditional frameworks of “acquired platelet disorders,” which tend to focus on classic hematologic and pharmacologic causes. This review summarizes current evidence on acquired platelet disorders and emphasizes the clinical and pathophysiologic relevance of sepsis-induced platelet dysfunction.
- 11 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1638994
Open AccessAcquired platelet disorders
Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most recognized causes in clinical practice. Nevertheless, increasing evidence points to inflammation, particularly the profound dysregulation seen in sepsis, as a major contributor to abnormal platelet behavior. Although sepsis-associated platelet defects are frequent in practice and correlate with organ injury and adverse outcomes, they are rarely acknowledged in traditional frameworks of “acquired platelet disorders,” which tend to focus on classic hematologic and pharmacologic causes. This review summarizes current evidence on acquired platelet disorders and emphasizes the clinical and pathophysiologic relevance of sepsis-induced platelet dysfunction.
- Open Access
- 26 December 2023
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (2) , 362-374
Evaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts
Introduction: Light transmission aggregometry (LTA) is important for diagnosing platelet function disorders (PFD) and von Willebrand disease (VWD) affecting ristocetin‐induced platelet aggregation (RIPA). Nonetheless, data is lacking on the utility of LTA for investigating thrombocytopenic patients and platelet rich plasma samples with low platelet counts (L‐PRP). Previously, we developed a strategy for diagnostic LTA assessment of L‐PRP that included: (1) acceptance of referrals/samples, regardless of thrombocytopenia severity, (2) tailored agonist selection, based on which are informative for L‐PRP with mildly or severely low platelet counts, and (3) interpretation of maximal aggregation (MA) using regression‐derived 95% confidence intervals, determined for diluted control L‐PRP (C‐L‐PRP).Methods: To further evaluate the L‐PRP LTA strategy, we evaluated findings for a subsequent patient cohort.Results: Between 2008 and 2021, the L‐PRP strategy was applied to 211 samples (11.7% of all LTA samples) from 192 unique patients, whose platelet counts (median [range] × 109/L) for blood and L‐PRP were: 105 [13–282; 89% with thrombocytopenia] and 164 [17–249], respectively. Patient‐L‐PRP had more abnormal MA findings than simultaneously tested C‐L‐PRP (p‐values n = 181), L‐PRP LTA uncovered significant aggregation abnormalities in 45 (24.9%), including 18/30 (60%) with 9 platelets/L L‐PRP, and ruled out PFD, and VWD affecting RIPA, in others. The L‐PRP LTA strategy helped diagnose VWD affecting RIPA, Bernard Soulier syndrome, familial platelet disorder with myeloid malignancy, suspected ITGA2B/ITGB3‐related thrombocytopenia, and acquired PFD.Conclusion: Diagnostic LTA with L‐PRP, using a strategy that considers thrombocytopenia severity, is feasible and informative.
- 26 December 2023
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (2) , 362-374
Open AccessEvaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts
Introduction: Light transmission aggregometry (LTA) is important for diagnosing platelet function disorders (PFD) and von Willebrand disease (VWD) affecting ristocetin‐induced platelet aggregation (RIPA). Nonetheless, data is lacking on the utility of LTA for investigating thrombocytopenic patients and platelet rich plasma samples with low platelet counts (L‐PRP). Previously, we developed a strategy for diagnostic LTA assessment of L‐PRP that included: (1) acceptance of referrals/samples, regardless of thrombocytopenia severity, (2) tailored agonist selection, based on which are informative for L‐PRP with mildly or severely low platelet counts, and (3) interpretation of maximal aggregation (MA) using regression‐derived 95% confidence intervals, determined for diluted control L‐PRP (C‐L‐PRP).Methods: To further evaluate the L‐PRP LTA strategy, we evaluated findings for a subsequent patient cohort.Results: Between 2008 and 2021, the L‐PRP strategy was applied to 211 samples (11.7% of all LTA samples) from 192 unique patients, whose platelet counts (median [range] × 109/L) for blood and L‐PRP were: 105 [13–282; 89% with thrombocytopenia] and 164 [17–249], respectively. Patient‐L‐PRP had more abnormal MA findings than simultaneously tested C‐L‐PRP (p‐values n = 181), L‐PRP LTA uncovered significant aggregation abnormalities in 45 (24.9%), including 18/30 (60%) with 9 platelets/L L‐PRP, and ruled out PFD, and VWD affecting RIPA, in others. The L‐PRP LTA strategy helped diagnose VWD affecting RIPA, Bernard Soulier syndrome, familial platelet disorder with myeloid malignancy, suspected ITGA2B/ITGB3‐related thrombocytopenia, and acquired PFD.Conclusion: Diagnostic LTA with L‐PRP, using a strategy that considers thrombocytopenia severity, is feasible and informative.
- Open Access
- 13 December 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (12) , e8305
An unusual non‐hematopoietic bone marrow finding
Key Clinical Message: We present an interesting case that showed a non‐hematopoietic structure embedded in the bone marrow biopsy. Given the clinical and morphological difficulties, it was challenging to identify this artifact's nature. Publishing this case would familiarize pathologists with this artifact and save additional testing and delays in reporting.
- 13 December 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (12) , e8305
Open AccessAn unusual non‐hematopoietic bone marrow finding
Key Clinical Message: We present an interesting case that showed a non‐hematopoietic structure embedded in the bone marrow biopsy. Given the clinical and morphological difficulties, it was challenging to identify this artifact's nature. Publishing this case would familiarize pathologists with this artifact and save additional testing and delays in reporting.
- Open Access
- 6 July 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (7) , e07637
Favorable outcome of PML‐RARα short isoform and FLT3‐ITD mutation in a patient with several adverse prognostic markers: A case report
Key Clinical Message: Complete molecular remission in a “variant APL” patient with short isoform of PML‐RARα and FLT3‐ITD mutation was achieved in response to ATRA and ATO plus IDA instead of standard treatment protocol. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3‐ITD. FLT3‐ITD mutations are the most common activating mutations in FLT3 gene, occurring in about 12 to 38% of acute promyelocytic leukemia cases, and are mainly associated with high white blood cell counts and poor clinical outcomes. Here, we present a case of APL variant with adverse prognostic features who showed short isoform [bcr3] of PML‐RARα and FLT3‐ITD mutation at diagnosis. The patient received all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) instead of standard treatment protocol, and achieved a complete morphological, cytogenetic and molecular response. However, the patient experienced differentiation syndrome, and coagulopathy that was subsequently resolved by continuous oxygen therapy, dexamethasone, and enoxaparin. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy in patients with FLT3‐ITD mutation.
- 6 July 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (7) , e07637
Open AccessFavorable outcome of PML‐RARα short isoform and FLT3‐ITD mutation in a patient with several adverse prognostic markers: A case report
Key Clinical Message: Complete molecular remission in a “variant APL” patient with short isoform of PML‐RARα and FLT3‐ITD mutation was achieved in response to ATRA and ATO plus IDA instead of standard treatment protocol. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3‐ITD. FLT3‐ITD mutations are the most common activating mutations in FLT3 gene, occurring in about 12 to 38% of acute promyelocytic leukemia cases, and are mainly associated with high white blood cell counts and poor clinical outcomes. Here, we present a case of APL variant with adverse prognostic features who showed short isoform [bcr3] of PML‐RARα and FLT3‐ITD mutation at diagnosis. The patient received all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) instead of standard treatment protocol, and achieved a complete morphological, cytogenetic and molecular response. However, the patient experienced differentiation syndrome, and coagulopathy that was subsequently resolved by continuous oxygen therapy, dexamethasone, and enoxaparin. The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy in patients with FLT3‐ITD mutation.
- Open Access
- 16 April 2023
- Published by Wiley
Outcome of PML-RARα Short Isoform and FLT3-ITD in a Patient with Several Adverse Prognostic Markers: a Case Report
Title: Outcome of PML-RARα Short Isoform and FLT3-ITD in a Patient with Several Adverse Prognostic Markers: a Case ReportMohammed A Bafail1, Rahaf AlTahan1Manar A Samman1, Suha A Tashkandi1, Ibraheem H Motabi2 , Abdul Ali Peer-Zada1*
- 16 April 2023
- Published by Wiley
Open AccessOutcome of PML-RARα Short Isoform and FLT3-ITD in a Patient with Several Adverse Prognostic Markers: a Case Report
Title: Outcome of PML-RARα Short Isoform and FLT3-ITD in a Patient with Several Adverse Prognostic Markers: a Case ReportMohammed A Bafail1, Rahaf AlTahan1Manar A Samman1, Suha A Tashkandi1, Ibraheem H Motabi2 , Abdul Ali Peer-Zada1*
- Open Access
- 12 August 2022
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 23, e936448-1-e936448-6
Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement
Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement - Article abstract #936448
- 12 August 2022
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 23, e936448-1-e936448-6
Open AccessRelapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement
Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement - Article abstract #936448
- Open Access
- 30 July 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (9) , 1809-1810
The unusual abundance of a rare finding!
We present images (Figure 1A‐D) of a preterm girl who had severe anemia due to HDFN caused by maternal anti‐C and anti‐D alloantibodies. These images show erythrophagocytosis, which is a very interesting and rarely encountered feature. We believe that physicians taking care of such patients should be more aware of this characteristic yet under‐detected finding.
- 30 July 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (9) , 1809-1810
Open AccessThe unusual abundance of a rare finding!
We present images (Figure 1A‐D) of a preterm girl who had severe anemia due to HDFN caused by maternal anti‐C and anti‐D alloantibodies. These images show erythrophagocytosis, which is a very interesting and rarely encountered feature. We believe that physicians taking care of such patients should be more aware of this characteristic yet under‐detected finding.
- Open Access
- 10 February 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (3) , 558-563
Non‐acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)
Key Clinical Message: t(11;17) is a rare but recognized finding usually found in Acute Promyelocytic Leukemia with variant RARA translocation (APLv). We present a case of Acute Myeloid Leukemia with t(11;17) that has different break points than those occurring in APLv. The diagnosis of acute myeloid leukemia, not otherwise specified, acute monoblastic leukemia was reached after a thorough investigation. Reaching the correct diagnosis and distinguishing these two entities are essential as they have different management, prognosis, and overall survival.
- 10 February 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (3) , 558-563
Open AccessNon‐acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17)
Key Clinical Message: t(11;17) is a rare but recognized finding usually found in Acute Promyelocytic Leukemia with variant RARA translocation (APLv). We present a case of Acute Myeloid Leukemia with t(11;17) that has different break points than those occurring in APLv. The diagnosis of acute myeloid leukemia, not otherwise specified, acute monoblastic leukemia was reached after a thorough investigation. Reaching the correct diagnosis and distinguishing these two entities are essential as they have different management, prognosis, and overall survival.